CPPS 306 VERIFIED STUDY GUIDE
Bosentan - Answers - first drug for the antagonism of ETA and ETB (didn't work that
well, due to no vasodilation pathways)
main use pulmonary hypertension
Ambrisentan - Answers - ETA selective theoretically provides an antihypertensive effect
allowed ETB receptors to release NO from endothelial cells
main use pulmonary hypertension
NO nitric oxide - Answers - NO can be thought of as a vasorelaxant equivalent of ET
NO is released from the endothelial cells into vascular smooth muscle
promotes the activity of guanylate cyclase (sGC) which then promotes cyclic GMP
this reduces intracellular CA2+ resulting in vasodilation
Riociguat - Answers - directly stimulates activity of soluble guanylate cyclase (used for
pulimary hypertension)
lowering intercellular calcium
Prostacyclin - Answers - mainly used for pulmonary hypertension
stimulates AC to produce more cAMP, which reduces intercellular CA2+
therefore prostacyclin relaxes blood vessels in the pulmonary circulation
Endothelial derived hyperpolarizing factor (EDHF) - Answers - Release of EDHF results
in opening of calcium channel, and hyperpolarization
hyperpolarization inhibits calcium channel, preventing entry of Ca2+ into the vasscular
smooth mussle resulting in relaxation (dilation over constriction)
Thiazides (group) - Answers - most commonly used diretic
Furosemide - Answers - Loop diretic (forces people to go to the bathroom alot< high
chance that patient stops taking medication beacuse of this)
Spironolactone - Answers - K+ sparing diretic prevents potasium loss
Angiotensisn II - Answers - Binds to the AT1 receptor
main physiological actions include
Aldosterone synthesis and secretion
NaCl reabsorption
Antidiuretic hormone (ADH) release
******vasoconstriction through an increase in Ca2+ in the vascular smooth muscle
Ramipril - Answers - all ACE inhibitors end in -pril
, inhibits vasoconstriction
inhibits aldosterone secretion (Na retention)
Inhibits NaCL reabsobtion
inhibit ADH release
****increased vasodilation through BK
result Decreased SVR
and an increase in natriuresis and diuresis
Losartan - Answers - Angiotensing receptor blockers (ARBs)
no effect on bradykinin
less cough
less angioedema
Aliskiren - Answers - Direct renin inhibitors (DRI)
theory patients 'resistant' to other RAS inhibitors might respond well to DRI
practice DRI has not been popular, first in the line of drugs
Nifedipine - Answers - (-ipine)
Dihydropyridines act on the vasculature > heart
pharmacodynamics
vasodilation (primary)
arterial>venous
reduces contractility
*****mainly dilates
Verapamil and Diltiazem - Answers - non-dihydropyridines
both have a greater impact on the heart than dihydropyridines but still, retain vascular
effects
pharmacodynamic actions
reduce heart rate
reduce contractility
vasodilation
nifedipine - Answers - rapid onset calcium blocker
Amlodipine - Answers - slower onset calcium blocker
Propranolol - Answers - Beta antagonist blockers
(-lol)
pharmacodynamic actions
decrease heart rate, contractility (b1)
decrease renin secretion (b1)
decrease SNS activity (b1)
Bosentan - Answers - first drug for the antagonism of ETA and ETB (didn't work that
well, due to no vasodilation pathways)
main use pulmonary hypertension
Ambrisentan - Answers - ETA selective theoretically provides an antihypertensive effect
allowed ETB receptors to release NO from endothelial cells
main use pulmonary hypertension
NO nitric oxide - Answers - NO can be thought of as a vasorelaxant equivalent of ET
NO is released from the endothelial cells into vascular smooth muscle
promotes the activity of guanylate cyclase (sGC) which then promotes cyclic GMP
this reduces intracellular CA2+ resulting in vasodilation
Riociguat - Answers - directly stimulates activity of soluble guanylate cyclase (used for
pulimary hypertension)
lowering intercellular calcium
Prostacyclin - Answers - mainly used for pulmonary hypertension
stimulates AC to produce more cAMP, which reduces intercellular CA2+
therefore prostacyclin relaxes blood vessels in the pulmonary circulation
Endothelial derived hyperpolarizing factor (EDHF) - Answers - Release of EDHF results
in opening of calcium channel, and hyperpolarization
hyperpolarization inhibits calcium channel, preventing entry of Ca2+ into the vasscular
smooth mussle resulting in relaxation (dilation over constriction)
Thiazides (group) - Answers - most commonly used diretic
Furosemide - Answers - Loop diretic (forces people to go to the bathroom alot< high
chance that patient stops taking medication beacuse of this)
Spironolactone - Answers - K+ sparing diretic prevents potasium loss
Angiotensisn II - Answers - Binds to the AT1 receptor
main physiological actions include
Aldosterone synthesis and secretion
NaCl reabsorption
Antidiuretic hormone (ADH) release
******vasoconstriction through an increase in Ca2+ in the vascular smooth muscle
Ramipril - Answers - all ACE inhibitors end in -pril
, inhibits vasoconstriction
inhibits aldosterone secretion (Na retention)
Inhibits NaCL reabsobtion
inhibit ADH release
****increased vasodilation through BK
result Decreased SVR
and an increase in natriuresis and diuresis
Losartan - Answers - Angiotensing receptor blockers (ARBs)
no effect on bradykinin
less cough
less angioedema
Aliskiren - Answers - Direct renin inhibitors (DRI)
theory patients 'resistant' to other RAS inhibitors might respond well to DRI
practice DRI has not been popular, first in the line of drugs
Nifedipine - Answers - (-ipine)
Dihydropyridines act on the vasculature > heart
pharmacodynamics
vasodilation (primary)
arterial>venous
reduces contractility
*****mainly dilates
Verapamil and Diltiazem - Answers - non-dihydropyridines
both have a greater impact on the heart than dihydropyridines but still, retain vascular
effects
pharmacodynamic actions
reduce heart rate
reduce contractility
vasodilation
nifedipine - Answers - rapid onset calcium blocker
Amlodipine - Answers - slower onset calcium blocker
Propranolol - Answers - Beta antagonist blockers
(-lol)
pharmacodynamic actions
decrease heart rate, contractility (b1)
decrease renin secretion (b1)
decrease SNS activity (b1)